Filtered By:
Specialty: Drugs & Pharmacology
Drug: Nicotine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 585 results found since Jan 2013.
Withdrawal from repeated nicotine vapor exposure increases somatic signs of physical dependence, anxiety-like behavior, and brain reward thresholds in adult male rats
In this study we assessed markers of withdrawal following 14 days of nicotine vapor exposure. For Experiment 1, 21 adult male rats were exposed to air or nicotine vapor for 14 consecutive days. Following exposure on day 14, rats were injected with the nicotinic receptor antagonist mecamylamine (3.0 mg/mL) and assessed for somatic withdrawal signs and anxiety-like behavior in the elevated plus maze. For Experiment 2, 12 adult male rats were tested for intracranial self-stimulation (ICSS) immediately following exposure to vehicle vapor (50%/50%, vegetable glycerin/propylene glycol) or nicotine vapor, for 14 consecutive days....
Source: Neuropharmacology - August 23, 2023 Category: Drugs & Pharmacology Authors: Michelle Mart ínez Veronika E Espinoza Valeria Garcia Kevin P Uribe Kenichiro Negishi Igor L Estevao Luis M Carcoba Laura E O'Dell Arshad M Khan Ian A Mendez Source Type: research
E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Continues: An Opportunity for Pharmacist Intervention
Ann Pharmacother. 2023 Aug 21:10600280231193770. doi: 10.1177/10600280231193770. Online ahead of print.ABSTRACTElectronic cigarette (e-cigarette), or vaping, product use-associated lung injury (EVALI) was first identified and reported in 2019, but media coverage and reporting of cases drastically decreased when the COVID-19 pandemic started in early 2020. The syndrome has continued to occur since that time and it is critical that pharmacists are aware of how EVALI presents, and when it should be considered as a potential diagnosis. Inpatient and outpatient pharmacists play a vital role in the treatment of EVALI, and should...
Source: The Annals of Pharmacotherapy - August 22, 2023 Category: Drugs & Pharmacology Authors: Miranda R Andrus Source Type: research
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Annu Rev Pharmacol Toxicol. 2023 Aug 16. doi: 10.1146/annurev-pharmtox-022123-104147. Online ahead of print.ABSTRACTThalidomide and its derivatives are powerful cancer therapeutics that are among the best-understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 ubiquitin ligase cereblon (CRBN) to commit target proteins for degradation by the ubiquitin-proteasome system. MGDs create novel recognition interfaces on the surface of the E3 ligase that engage in induced protein-protein interactions with neosubstrates. Molecular insight into their mechanism of action opens exciting opportunities to eng...
Source: Annual Review of Pharmacology and Toxicology - August 16, 2023 Category: Drugs & Pharmacology Authors: Vladas Oleinikovas Pablo Gainza Thomas Ryckmans Bernhard Fasching Nicolas H Thom ä Source Type: research
